SDGR Stock Analysis
SD
Uncovered
Schrodinger Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. The company is headquartered in New York City, New York and currently employs 787 full-time employees. The company went IPO on 2020-02-06. The software platform is used by biopharmaceutical and industrial companies, academic institutions and government laboratories around the world. The firm also leverages its software platform to advance collaborative programs and its own pipeline of therapeutics to address unmet medical needs. The firm operates through two segments: software and drug discovery. The software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on building a portfolio of preclinical and clinical programs, internally and through collaborations, which has advanced to various stages of discovery and development. The Company’s pipeline of drug discovery programs include MALT1, CDC7, Wee1, and SOS1/KRAS.